GH · Guardant Health, Inc.

Guardant Health’s Q1 2026 results reflect robust top-line acceleration—48% revenue growth driven by exceptional volume expansion: oncology tests rose 47% to 86,000, while Shield screening tests surged to 44,000 (up from 9,000), contributing to a >600% revenue increase in the screening segment. Oncology revenue grew 36%, underpinned by both volume and improved reimbursement, and Biopharma & Data revenue rose 17%, suggesting continued strength in partnerships and data monetization. Non-GAAP gross margin expanded 100 bps to 66%, reflecting operating leverage despite elevated commercial investment—evident in sales and marketing expense rising to $169.1M (up 62% YoY) and total operating expenses increasing to $318.1M. Management attributed growth to Smart platform adoption, InfinityAI real-world evidence integration, and strategic initiatives including the Quest collaboration and FDA approval of Guardant360 CDx for VEPPANU. The upward revision to full-year revenue guidance—from $1.25–$1.28B to $1.30–$1.32B—and tighter projections for Shield test volume (230K–245K) and oncology volume (>35% growth) signal confidence in sustained commercial scaling. Though GAAP net loss widened to $112.1M, the narrowing of non-GAAP net loss to $58.7M—and improved non-GAAP EPS to ($0.45) from ($0.49)—demonstrates progress toward profitability as infrastructure investments mature. With $1.2B in combined cash and marketable securities, the company maintains strong liquidity to fund its multi-year growth runway in precision oncology and cancer screening.